Enhancement of the Antitumor and Antimetastatic Effect of Topotecan and Normalization of Blood Counts in Mice with Lewis Carcinoma by Tdp1 Inhibitors-New Usnic Acid Derivatives.
Tatyana E KornienkoArina A ChepanovaAlexandra L ZakharenkoAleksandr S FilimonovOlga A LuzinaNadezhda S DyrkheevaValeriy P NikolinNelly A PopovaNariman F SalakhutdinovOlga I LavrikPublished in: International journal of molecular sciences (2024)
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme and one of the causes of tumor resistance to topoisomerase 1 inhibitors such as topotecan. Inhibitors of this Tdp1 in combination with topotecan may improve the effectiveness of therapy. In this work, we synthesized usnic acid derivatives, which are hybrids of its known derivatives: tumor sensitizers to topotecan. New compounds inhibit Tdp1 in the micromolar and submicromolar concentration range; some of them enhance the effect of topotecan on the metabolic activity of cells of various lines according to the MTT test. One of the new compounds (compound 7 ) not only sensitizes Krebs-2 and Lewis carcinomas of mice to the action of topotecan, but also normalizes the state of the peripheral blood of mice, which is disturbed in the presence of a tumor. Thus, the synthesized substances may be the prototype of a new class of additional therapy for cancer.
Keyphrases
- dna repair
- peripheral blood
- amyotrophic lateral sclerosis
- high fat diet induced
- induced apoptosis
- dna damage
- randomized controlled trial
- stem cells
- type diabetes
- cell cycle arrest
- papillary thyroid
- metabolic syndrome
- endoplasmic reticulum stress
- dna damage response
- signaling pathway
- drinking water
- circulating tumor
- skeletal muscle
- bone marrow
- cell therapy
- lymph node metastasis
- smoking cessation